IQVIA Stock News

Alibaba Group was a contributor during the quarter. The stock price rose significantly following earnings that reflected rapid Chinese AI growth. Alphabet was a contributor during the quarter. The stock price appreciated following a favorable ruling in the Google Search antitrust case and Q2 earnings that exceeded expectations across the board. Charter Communications was a detractor during the ...

IQVIA Holdings Inc. ( IQV ) UBS Global Healthcare Conference 2025 November 11, 2025 12:30 PM EST Company Participants Ari Bousbib - CEO & Chairman Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division All right. We're live.

Warner Bros Discovery reported merger with Paramount-Skydance could generate meaningful cost synergies and create a scaled competitor with a deep and unmatched content library. Innovations in the Google Search experience are driving both engagement and revenue benefits for Alphabet. IQVIA's R&D solutions business showed signs of gaining share, with its win rate improving significantly.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today. Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital in Boston and the Sidney Farber Professor of Medicin...

IQVIA Holdings Inc. (NYSE:IQV ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Kerri Joseph - SVP of Investment Relation & Treasury Ari Bousbib - CEO & Chairman Ronald Bruehlman - Executive VP & CFO Michael Fedock - Senior Vice President of Financial Planning and Analysis Conference Call Participants David Windley - Jefferies LLC, Research Division Justin Bowers - Deuts...

IQVIA Holdings on Tuesday narrowed its annual profit forecast, trimming the upper end of its outlook, as it expects cancellations of research contracts from pharmaceutical clients to persist into the second half of this year.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2025. Third-Quarter 2025 Operating Results Revenue for the third quarter of $4,100 mil...

We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron in our view has a strong balance sheet and a robust product pipeline.